| Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead |
2013-001225-11: Comparison of two medicines in heartr perfusion stress studies. Adenosiinin ja regadenosonin vertailu sydänlihaksen verenvirtauksen PET tutkimuksessa sepelvaltimotautia sairastavilla potilailla |
|
|
| Ongoing | 4 | 30 | Europe | Adenocor, Rapidcan, Injection, Adenocor, Rapiscan | Turku University Hospital, Turku University Hospital, RapidScan Pharma/Cardirad Finland | Coronary artery desease Sepelvaltimotauti, Coronary artery desease Sepelvaltimotauti, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2022-001452-42: EVALUATION OF PATIENTS WITH TOTAL CORONARY OCCLUSIONS WITH MULTIMODALITY IMAGE EVALUACIÓN DE PACIENTES CON OCLUSIONES CRÓNICAS TOTALES CORONARIAS CON IMAGEN MULTIMODAL. |
|
|
| Not yet recruiting | 4 | 78 | Europe | Solution for injection, Rapiscan, Eufilina, Clariscan | HOSPITAL CLINIC BARCELONA, HOSPITAL CLINIC BARCELONA | Coronary artery chronic total occlusion Oclusión crónica total coronaria, Chronic total occlusion of an artery of the heart Obstrucción total de larga duración en arterias del corazón, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 4 | 376 | US | Regadenoson, Lexiscan | Paul Kim | Heart Transplant Failure and Rejection | 12/25 | 12/25 | | |
NCT02130453: Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking |
|
|
| Completed | 4 | 161 | US | Regadenoson | M.D. Anderson Cancer Center, Astellas Scientific & Medical Affairs, Inc. | Ischemia | 06/24 | 06/24 | | |
ChiCTR2400086198: Regadenoson Improve Microvascular dysfunction and Clinical Prognosis in STEMI patients undergoing primary percutaneous coronary intervention: a Randomised Controlled Trial (REVERSE) |
|
|
| Recruiting | 4 | 380 | | Reganosen was given 0.4mg intravenous infusion, and 10 minutes later, Reganosen was given 15ug/min maintenance treatment for 1 hour.; 0.4mg of normal saline was injected intravenously, and 15ug/min of normal saline was given for 1 hour after 10 minutes.; Reganosen was given 0.4mg intravenous infusion, and 10 minutes later, Reganosen was given 15ug/min maintenance treatment for 1 hour. | Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University, Fudan University Affiliated Zhongshan Hospital 2023 Special fund for clinical research | Coronary heart disease | | | | |
| Not yet recruiting | 2 | 98 | Europe | Rapiscan, Injection, Rapiscan | Queen Mary University London, Bart's Charity, J P Moulton Charitable Foundation | Cardiovascular collapse following traumatic haemorrhage, Heart failure caused by major bleeding after injury, Diseases [C] - Injuries, poisonings, and occupational diseases [C21] | | | | |
NCT05583721: Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET |
|
|
| Recruiting | 2 | 40 | US | [13N]NH3, [N-13] Ammonia, azane, CAS# 34819-78-8, Lexiscan, Regadenoson, Positron emission tomography, PET | St. Jude Children's Research Hospital | Sickle Cell Disease | 09/25 | 09/26 | | |
2019-002615-25: A clinical trial to be conducted in many hospitals and in different countrieswith the medicinal substance Regadenoson to be used in a type of heart scan called ‘radionuclide myocardial perfusion imaging’ to see the blood flow in the heart muscle in patients aged between 1 month - 18 years. |
|
|
| Not yet recruiting | 1/2 | 54 | Europe | Regadenoson, [-], Solution for injection, Rapiscan | GE Healthcare Ltd., GE HEALTHCARE, GE Healthcare Ltd. | Patients who need to undergo a clinically indicated pharmacologic stress perfusion CMR test and who are considered fit for a pharmacological stress perfusion CMR by the investigator. The pharmacologic stress perfusion CMR may be performed in patients for further evaluation of cardiovascular conditions or diseases, such as, but not limited to, Kawasaki disease, congenital heart diseases, congenital coronary abnormalities, and post-cardiac surgery / transplantation, etc., Rapiscan is used in a type of heart scan called myocardial perfusion imaging. It belongs to a group of medicines called coronary vasodilators. It makes heart arteries expand and heart rate increase., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Completed | 1/2 | 5 | US | Regadenoson, LEXISCAN,, Placebo Control, Saline | University of Maryland, Baltimore | COVID-19, Lung Inflammation | 04/23 | 04/23 | | |
| Recruiting | 1/2 | 54 | Europe | Regadenoson, Rapiscan | GE Healthcare, Covance | Myocardial Ischemia, Coronary Artery Disease | 12/26 | 12/26 | | |
NCT04600115: New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Recruiting | 1 | 100 | US | Adenosine, Adenoscan, Adenocard, Regadenoson, Lexiscan, O-15 labeled radioactive water, O-15 water, MRI, PET Imaging, Positron Emission Tomography Imaging | University of Utah, National Heart, Lung, and Blood Institute (NHLBI) | MRI Scans | 03/22 | 03/23 | | |
NCT03971734: Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas |
|
|
| Terminated | 1 | 7 | US | Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma | 04/22 | 10/23 | | |
NCT04521569: Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System |
|
|
| Completed | 1 | 47 | US | Regadenoson, Lexiscan, Placebo, Steen solution | University of Maryland, Baltimore, National Heart, Lung, and Blood Institute (NHLBI) | Lung Transplant | 06/24 | 07/24 | | |
RJNS-NJHM01, ChiCTR1800014649: Evaluation of the Accuracy and Safety of Regadenoson Injection as A Stress Drug of Myocardial Perfusion Imaging (MPI), A Multicenter, Random, Open, Adenosine Positive Control trial |
|
|
| Recruiting | N/A | | | | Fudan University Affiliated Zhongshan Hospital; Nanjing Healmed Biological Medicine Company, Nanjing Healmed Biological Medicine Company | coronary artery disease | | | | |
| Completed | N/A | 91 | US | regadenoson infusion with contrast-enhanced ultrasound, Lexiscan, regadenoson, contrast-enhanced ultrasound | Versiti, Medical College of Wisconsin, La Jolla Institute for Allergy & Immunology, University of Illinois at Chicago, Oregon Health and Science University, Dana-Farber Cancer Institute | Sickle Cell Disease, Sickle Cell Anemia | 07/19 | 11/20 | | |
NCT01719016: Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics |
|
|
| Active, not recruiting | N/A | 68 | US | Cardiac PET, Coronary catheterization, Volcano therapeutics, Combomap machine, Adenosine, Lexiscan, N-13 Ammonia | University of Cincinnati | Coronary Artery Disease | 06/24 | 06/24 | | |
NCT04316676: The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI |
|
|
| Recruiting | N/A | 20 | US | PET-MPI Protocol, CT-MPI, CT-FFR, Regadenoson, Lexiscan | Emory University, Siemens Medical Solutions | Coronary Artery Disease | 12/24 | 12/24 | | |
NCT06246188: Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients With Known or Suspected Coronary Artery Disease |
|
|
| Not yet recruiting | N/A | 80 | Europe | Cardiac MRI using Regadenoson and GE-267 | German Heart Institute, GE Healthcare | Coronary Artery Disease | 11/24 | 07/25 | | |
NCT03064295: Whole-Heart Myocardial Blood Flow Quantification Using MRI |
|
|
| Recruiting | N/A | 160 | US | Myocardial Perfusion Cardiac MRI., Myocardial Perfusion imaging, Myocardial Perfusion CMR, Magnetic Resonance Imaging, First Pass Myocardial Perfusion Imaging, Contrast, contrast media, Gadavist, MultiHance, Pharmacologic Stress Agent, regadenoson, adenosine, stress agent | Cedars-Sinai Medical Center, National Heart, Lung, and Blood Institute (NHLBI) | Coronary Artery Disease, Coronary Microvascular Disease | 01/25 | 01/25 | | |
